Loading...

Stephen Stahl

TitleAdjunct Professor
InstitutionUniversity of California San Diego
DepartmentPsychiatry
Address9500 Gilman Drive #9116A
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    HUMAN 5HT RECEPTOR REGULATION BY ANTIDEPRESSANTS
    NIH/NIMH R01MH045787Sep 1, 1991 - Jan 31, 1995
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Stahl S. Antagonist treatment is just as effective as replacement therapy for opioid addiction but neither is used often enough. CNS Spectr. 2018 Apr; 23(2):113-116. PMID: 29676241.
      View in: PubMed
    2. Marazziti D, Stahl S. Serotonin and Love: Supporting Evidence From a Patient Suffering From Obsessive-Compulsive Disorder. J Clin Psychopharmacol. 2018 Feb; 38(1):99-101. PMID: 29189409.
      View in: PubMed
    3. Stahl S. Mixed-up about how to diagnose and treat mixed features in major depressive episodes - CORRIGENDUM. CNS Spectr. 2018 Apr; 23(2):185. PMID: 29353558.
      View in: PubMed
    4. Cummings MA, Proctor GJ, Stahl S. Deuterium Tetrabenazine for Tardive Dyskinesia. Clin Schizophr Relat Psychoses. 2018 Jan; 11(4):214-220. PMID: 29341821.
      View in: PubMed
    5. Stahl S. Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects. CNS Spectr. 2018 Feb; 23(1):1-6. PMID: 29249207.
      View in: PubMed
    6. Stahl S. Neuronal traffic signals in tardive dyskinesia: not enough "stop" in the motor striatum. CNS Spectr. 2017 Dec; 22(6):427-434. PMID: 29205123.
      View in: PubMed
    7. Lemoine P, Stahl S. Conditions of life and death of psychiatric patients in France during World War II: euthanasia or collateral casualties? CNS Spectr. 2018 Apr; 23(2):170-175. PMID: 29081316.
      View in: PubMed
    8. Stahl S. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr. 2017 Oct; 22(5):375-384. PMID: 28965530.
      View in: PubMed
    9. Stahl S, Morrissette DA. Does a "whiff" of mania in a major depressive episode shift treatment from a classical antidepressant to an atypical/second-generation antipsychotic? Bipolar Disord. 2017 11; 19(7):595-596. PMID: 28895270.
      View in: PubMed
    10. Marazziti D, Stahl S. Evil, terrorism, and psychiatry. CNS Spectr. 2018 Apr; 23(2):117-118. PMID: 28870267.
      View in: PubMed
    11. Stahl S. Dazzled by the dominions of dopamine: clinical roles of D3, D2, and D1 receptors. CNS Spectr. 2017 Aug; 22(4):305-311. PMID: 28758887.
      View in: PubMed
    12. Moore BA, Morrissette DA, Meyer JM, Stahl S. Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing. BJPsych Bull. 2017 Jun; 41(3):164-168. PMID: 28584654.
      View in: PubMed
    13. Shapiro D, Stevens D, Stahl S. Flibanserin - the female Viagra? Int J Psychiatry Clin Pract. 2017 Nov; 21(4):259-265. PMID: 28434386.
      View in: PubMed
    14. Stahl S. Does treating hearing loss prevent or slow the progress of dementia? Hearing is not all in the ears, but who's listening? CNS Spectr. 2017 Jun; 22(3):247-250. PMID: 28376938.
      View in: PubMed
    15. Keppel Hesselink JM, Kopsky DJ, Stahl S. Bottlenecks in the development of topical analgesics: molecule, formulation, dose-finding, and phase III design. J Pain Res. 2017; 10:635-641. PMID: 28360532.
      View in: PubMed
    16. Stahl S. Mixed-up about how to diagnose and treat mixed features in major depressive episodes. CNS Spectr. 2017 Apr; 22(2):111-115. PMID: 28271818.
      View in: PubMed
    17. Stahl S, Morrissette DA, Faedda G, Fava M, Goldberg JF, Keck PE, Lee Y, Malhi G, Marangoni C, McElroy SL, Ostacher M, Rosenblat JD, Solé E, Suppes T, Takeshima M, Thase ME, Vieta E, Young A, Zimmerman M, McIntyre RS. Guidelines for the recognition and management of mixed depression. CNS Spectr. 2017 Apr; 22(2):203-219. PMID: 28421980.
      View in: PubMed
    18. Stahl S. Psychiatric Pharmacogenomics: How to Integrate into Clinical Practice. CNS Spectr. 2017 Feb; 22(1):1-4. PMID: 28168945.
      View in: PubMed
    19. Stahl S. Kick-Off Editorial for 2017: CNS Spectrums Is on the Move. CNS Spectr. 2017 Feb; 22(1):5-6. PMID: 28168944.
      View in: PubMed
    20. Nutt D, Stahl S, Blier P, Drago F, Zohar J, Wilson S. Inverse agonists - What do they mean for psychiatry? Eur Neuropsychopharmacol. 2017 01; 27(1):87-90. PMID: 27955830.
      View in: PubMed
    21. Meyer JM, Cummings MA, Proctor G, Stahl S. Psychopharmacology of Persistent Violence and Aggression. Psychiatr Clin North Am. 2016 Dec; 39(4):541-556. PMID: 27836150.
      View in: PubMed
    22. Stahl S. Dextromethorphan-quinidine-responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression? CNS Spectr. 2016 Dec; 21(6):419-423. PMID: 27855728.
      View in: PubMed
    23. Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl S, Wallen K, Worsley R. Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. Mayo Clin Proc. 2017 Jan; 92(1):114-128. PMID: 27916394.
      View in: PubMed
    24. Meyer JM, Proctor G, Cummings MA, Dardashti LJ, Stahl S. Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction. Case Rep Psychiatry. 2016; 2016:5606098. PMID: 27872784.
      View in: PubMed
    25. Stahl S. Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectr. 2016 Oct; 21(5):355-359. PMID: 27686027.
      View in: PubMed
    26. Stahl S. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. CNS Spectr. 2016 Aug; 21(4):271-5. PMID: 27503570.
      View in: PubMed
    27. Stahl S. Mechanism of action of suvorexant. CNS Spectr. 2016 Jun; 21(3):215-8. PMID: 27322687.
      View in: PubMed
    28. Stahl S. Using neuroscience for naming psychotropic drugs. CNS Spectr. 2016 Jun; 21(3):219-20. PMID: 27322688.
      View in: PubMed
    29. Stahl S. Mechanism of action of cariprazine. CNS Spectr. 2016 Apr; 21(2):123-7. PMID: 26956157.
      View in: PubMed
    30. Stahl S. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 2016 Feb; 21(1):1-6. PMID: 26899451.
      View in: PubMed
    31. Zohar J, Stahl S, Moller HJ, Blier P, Kupfer D, Yamawaki S, Uchida H, Spedding M, Goodwin GM, Nutt D. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol. 2015 Dec; 25(12):2318-25. PMID: 26527055.
      View in: PubMed
    32. Culpepper L, Muskin PR, Stahl S. Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability. Am J Med. 2015 Sep; 128(9 Suppl):S1-S15. PMID: 26337210.
      View in: PubMed
    33. Stahl S. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine. CNS Spectr. 2015 Oct; 20(5):455-9. PMID: 26122791.
      View in: PubMed
    34. Stahl S. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release. CNS Spectr. 2015 Aug; 20(4):331-6. PMID: 26062900.
      View in: PubMed
    35. Stahl S. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters. CNS Spectr. 2015 Dec; 20(6):515-9. PMID: 26062986.
      View in: PubMed
    36. Warburton KD, Stahl S. Treat the treatable: a comprehensive and optimistic approach to treating psychiatric violence. CNS Spectr. 2015 Jun; 20(3):170-1. PMID: 25997604.
      View in: PubMed
    37. Stahl S. Is impulsive violence an addiction? The Habit Hypothesis. CNS Spectr. 2015 Jun; 20(3):165-9. PMID: 25912294.
      View in: PubMed
    38. Stahl S. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr. 2015 Apr; 20(2):93-7. PMID: 25831967.
      View in: PubMed
    39. Schaufenbil RJ, Kornbluh R, Stahl S, Warburton KD. Forensic focused treatment planning: a new standard for forensic mental health systems. CNS Spectr. 2015 Jun; 20(3):250-3. PMID: 25801440.
      View in: PubMed
    40. Morrissette DA, Stahl S. Modulating the serotonin system in the treatment of major depressive disorder-ERRATUM. CNS Spectr. 2015 Aug; 20(4):452-3. PMID: 25731078.
      View in: PubMed
    41. Stahl S. Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr. 2015 Feb; 20(1):1-6. PMID: 25659981.
      View in: PubMed
    42. Morrissette DA, Stahl S. Modulating the serotonin system in the treatment of major depressive disorder. CNS Spectr. 2014 Dec; 19 Suppl 1:57-67; quiz 54-7, 68. PMID: 25544378.
      View in: PubMed
    43. Stahl S. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients. CNS Spectr. 2014 Dec; 19(6):475-8. PMID: 25422900.
      View in: PubMed
    44. Stahl S. Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits. CNS Spectr. 2014 Oct; 19(5):357-65. PMID: 25296964.
      View in: PubMed
    45. Stahl S, Morrissette DA, Cummings M, Azizian A, Bader S, Broderick C, Dardashti L, Delgado D, Meyer J, O'Day J, Proctor G, Rose B, Schur M, Schwartz E, Velasquez S, Warburton K. California State Hospital Violence Assessment and Treatment (Cal-VAT) guideline. CNS Spectr. 2014 Oct; 19(5):449-65. PMID: 27358935.
      View in: PubMed
    46. Stahl S, Morrissette DA, Cummings M, Azizian A, Bader S, Broderick C, Dardashti L, Delgado D, Meyer J, O'Day J, Proctor G, Rose B, Schur M, Schwartz E, Velasquez S, Warburton K. California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectr. 2014 Oct; 19(5):449-465. PMID: 28480838.
      View in: PubMed
    47. Morrissette DA, Stahl S. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr. 2014 Oct; 19(5):439-48. PMID: 25119976.
      View in: PubMed
    48. Stahl S. Clozapine: is now the time for more clinicians to adopt this orphan? CNS Spectr. 2014 Aug; 19(4):279-81. PMID: 25267329.
      View in: PubMed
    49. Papakostas GI, Shelton RC, Zajecka JM, Bottiglieri T, Roffman J, Cassiello C, Stahl S, Fava M. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014 Aug; 75(8):855-63. PMID: 24813065.
      View in: PubMed
    50. Stahl S. Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. CNS Spectr. 2014 Jun; 19(3):207-12. PMID: 24901504.
      View in: PubMed
    51. Stahl S. Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor. CNS Spectr. 2014 Apr; 19(2):105-9. PMID: 24673885.
      View in: PubMed
    52. Stahl S. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014 Feb; 19(1):3-5. PMID: 24512639.
      View in: PubMed
    53. Stahl S. Role of a1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectr. 2013 Dec; 18(6):285-8. PMID: 24300463.
      View in: PubMed
    54. Grady MM, Stahl S. Novel agents in development for the treatment of depression. CNS Spectr. 2013 Dec; 18 Suppl 1:37-40; quiz 41. PMID: 24252548.
      View in: PubMed
    55. Opler LA, Medalia A, Opler MG, Stahl S. Pharmacotherapy of cognitive deficits in schizophrenia. CNS Spectr. 2014 Apr; 19(2):142-56. PMID: 24229725.
      View in: PubMed
    56. Stahl S. Mechanism of action of dextromethorphan/quinidine:comparison with ketamine. CNS Spectr. 2013 Oct; 18(5):225-7. PMID: 24050154.
      View in: PubMed
    57. Zohar J, Nutt DJ, Kupfer DJ, Moller HJ, Yamawaki S, Spedding M, Stahl S. A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol. 2014 Jul; 24(7):1005-14. PMID: 24630385.
      View in: PubMed
    58. Stahl S. Controversies in treating bipolar depression. CNS Spectr. 2013 Aug; 18(4):175-6. PMID: 23866090.
      View in: PubMed
    59. Translating from neuroscience to psychiatry (and back translating from psychiatry to neuroscience). Acta Psychiatr Scand. 2013 Aug; 128(2):103-4. PMID: 23829230.
      View in: PubMed
    60. Stahl S. Mechanism of action of ketamine. CNS Spectr. 2013 Aug; 18(4):171-4. PMID: 23866089.
      View in: PubMed
    61. Stahl S, Morrissette DA, Citrome L, Saklad SR, Cummings MA, Meyer JM, O'Day JA, Dardashti LJ, Warburton KD. “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectr. 2013 Jun; 18(3):150-162. PMID: 23591126.
      View in: PubMed
    62. Stahl S. Classifying psychotropic drugs by mode of action and not by target disorder. CNS Spectr. 2013 Jun; 18(3):113-7. PMID: 23706705.
      View in: PubMed
    63. Stahl S, Porreca F, Taylor CP, Cheung R, Thorpe AJ, Clair A. The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities? Trends Pharmacol Sci. 2013 Jun; 34(6):332-9. PMID: 23642658.
      View in: PubMed
    64. Stahl S, Lee-Zimmerman C, Cartwright S, Morrissette DA. Serotonergic drugs for depression and beyond. Curr Drug Targets. 2013 May 01; 14(5):578-85. PMID: 23531115.
      View in: PubMed
    65. Stahl S. The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. CNS Spectr. 2013 Apr; 18(2):65-8. PMID: 23691552.
      View in: PubMed
    66. Stahl S, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013 May; 74(5):507-15. PMID: 23541189.
      View in: PubMed
    67. Stahl S. Emerging guidelines for the use of antipsychotic polypharmacy. Rev Psiquiatr Salud Ment. 2013 Jul-Sep; 6(3):97-100. PMID: 23485567.
      View in: PubMed
    68. Stahl S. Off-label prescribing: best practice or malpractice? CNS Spectr. 2013 Feb; 18(1):1-4. PMID: 23593650.
      View in: PubMed
    69. Stahl S. The tyranny of the majority and the interchangeability of drugs. Acta Psychiatr Scand. 2013 Jan; 127(1):4-5. PMID: 23240592.
      View in: PubMed
    70. Schwartz TL, Sachdeva S, Stahl S. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol. 2012; 3:195. PMID: 23189055; PMCID: PMC3505861.
    71. Morrissette DA, Stahl S. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment. CNS Spectr. 2012 Nov; 17 Suppl 1:10-21. PMID: 23462201.
      View in: PubMed
    72. Griebel G, Beeské S, Stahl S. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2012 Nov; 73(11):1403-11. PMID: 23146246.
      View in: PubMed
    73. Lum CT, Stahl S. Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS Spectr. 2012 Sep; 17(3):107-20. PMID: 23888494.
      View in: PubMed
    74. Tarazi FI, Stahl S. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep; 13(13):1911-22. PMID: 22849428.
      View in: PubMed
    75. Grady MM, Stahl S. A horse of a different color: how formulation influences medication effects. CNS Spectr. 2012 Jun; 17(2):63-9. PMID: 22789063.
      View in: PubMed
    76. Stahl S. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand. 2012 May; 125(5):349-51. PMID: 22506490.
      View in: PubMed
    77. Grady MM, Stahl S. Practical guide for prescribing MAOIs: debunking myths and removing barriers. CNS Spectr. 2012 Mar; 17(1):2-10. PMID: 22790112.
      View in: PubMed
    78. Brandt MR, Beyer CE, Stahl S. TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception. Pharmaceuticals (Basel). 2012 Feb 02; 5(2):114-32. PMID: 24288084; PMCID: PMC3763634.
    79. Schwartz TL, Sachdeva S, Stahl S. Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia. Curr Pharm Des. 2012; 18(12):1580-92. PMID: 22280435.
      View in: PubMed
    80. Citrome L, Meng X, Hochfeld M, Stahl S. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Hum Psychopharmacol. 2012 Jan; 27(1):24-32. PMID: 22161738.
      View in: PubMed
    81. Schwartz TL, Siddiqui UA, Stahl S. Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Ther Adv Psychopharmacol. 2011 Jun; 1(3):81-7. PMID: 23983930; PMCID: PMC3736894.
    82. Schwartz TL, Stahl S. Treatment strategies for dosing the second generation antipsychotics. CNS Neurosci Ther. 2011 Apr; 17(2):110-7. PMID: 21401911.
      View in: PubMed
    83. Mattei C, Rapagnani MP, Stahl S. Ziprasidone hydrocloride: what role in the management of schizophrenia? J Cent Nerv Syst Dis. 2011; 3:1-16. PMID: 23861634; PMCID: PMC3663608.
    84. Stahl S, Lonnen AJ. The Mechanism of Drug-induced Akathsia. CNS Spectr. 2011 Jan 15. PMID: 21406165.
      View in: PubMed
    85. Loonen AJ, Stahl S. Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders. Acta Psychiatr Scand. 2010 Dec; 122(6):435-7. PMID: 21054280.
      View in: PubMed
    86. Stahl S. The serotonin-7 receptor as a novel therapeutic target. J Clin Psychiatry. 2010 Nov; 71(11):1414-5. PMID: 21114946.
      View in: PubMed
    87. Stahl S. How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. Acta Psychiatr Scand. 2010 Dec; 122(6):440-1. PMID: 20880158.
      View in: PubMed
    88. Stahl S, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011 Jan; 8(1):15-27. PMID: 20840530.
      View in: PubMed
    89. Stahl S. Illustrating the circuits of sexual desire. J Clin Psychiatry. 2010 Sep; 71(9):1113-4. PMID: 20923619.
      View in: PubMed
    90. Stahl S, Malla A, Newcomer JW, Potkin SG, Weiden PJ, Harvey PD, Loebel A, Watsky E, Siu CO, Romano S. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. J Clin Psychopharmacol. 2010 Aug; 30(4):425-30. PMID: 20571437.
      View in: PubMed
    91. Stahl S, Davis RL, Kim DH, Lowe NG, Carlson RE, Fountain K, Grady MM. Play it Again: The Master Psychopharmacology Program as an Example of Interval Learning in Bite-Sized Portions. CNS Spectr. 2010 Aug; 15(8):491-504. PMID: 20703196.
      View in: PubMed
    92. Stahl S. Targeting circuits of sexual desire as a treatment strategy for hypoactive sexual desire disorder. J Clin Psychiatry. 2010 Jul; 71(7):821-2. PMID: 20667289.
      View in: PubMed
    93. Stahl S. Fooling mother nature: epigenetics and novel treatments for psychiatric disorders. CNS Spectr. 2010 Jun; 15(6):358-65. PMID: 20625368.
      View in: PubMed
    94. Stahl S. Psychiatric stress testing: novel strategy for translational psychopharmacology. Neuropsychopharmacology. 2010 Jun; 35(7):1413-4. PMID: 20463680; PMCID: PMC3055455.
    95. Stahl S. Circuits of sexual desire in hypoactive sexual desire disorder. J Clin Psychiatry. 2010 May; 71(5):518-9. PMID: 20492849.
      View in: PubMed
    96. Stahl S. Methylated spirits: epigenetic hypotheses of psychiatric disorders. CNS Spectr. 2010 Apr; 15(4):220-30. PMID: 20414171.
      View in: PubMed
    97. Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010 Apr; 30(2):135-44. PMID: 20520286.
      View in: PubMed
    98. Stahl S, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry. 2010 May; 71(5):616-26. PMID: 20361916.
      View in: PubMed
    99. Stahl S. Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms. J Clin Psychiatry. 2010 Mar; 71(3):223-4. PMID: 20331927.
      View in: PubMed
    100. Stahl S. Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectr. 2010 Feb; 15(2):79-94. PMID: 20414154.
      View in: PubMed
    101. Kim DH, Stahl S. Antipsychotic drug development. Curr Top Behav Neurosci. 2010; 4:123-39. PMID: 21312399.
      View in: PubMed
    102. Stahl S. Mechanism of action of stimulants in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010 Jan; 71(1):12-3. PMID: 20129003.
      View in: PubMed
    103. Stahl S. Crisis in army psychopharmacology and mental health care at Fort Hood. CNS Spectr. 2009 Dec; 14(12):677-84. PMID: 20394175.
      View in: PubMed
    104. Mignon L, Stahl S. Clinical management of major depressive disorder. CNS Spectr. 2009 Nov; 14(11 Suppl 10):3-6; quiz 7-8. PMID: 20173690.
      View in: PubMed
    105. Stahl S. Combining antidepressant therapies from the initiation of treatment: a paradigm shift for major depression. J Clin Psychiatry. 2009 Nov; 70(11):1493-4. PMID: 20031093.
      View in: PubMed
    106. Stahl S. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009 Oct; 14(10):536-46. PMID: 20095366.
      View in: PubMed
    107. Stahl S. Epigenetics and methylomics in psychiatry. J Clin Psychiatry. 2009 Sep; 70(9):1204-5. PMID: 19818242.
      View in: PubMed
    108. Stahl S, Davis RL. Applying the principles of adult learning to the teaching of psychopharmacology: audience response systems. CNS Spectr. 2009 Aug; 14(8):412-4. PMID: 19890234.
      View in: PubMed
    109. Stahl S. The prefrontal cortex is out of tune in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2009 Jul; 70(7):950-1. PMID: 19653972.
      View in: PubMed
    110. Stahl S, Davis RL. Applying the principles of adult learning to the teaching of psychopharmacology: storyboarding a presentation and the rule of small multiples. CNS Spectr. 2009 Jun; 14(6):288-94. PMID: 19668120.
      View in: PubMed
    111. Munk-Jørgensen P, Nielsen J, Nielsen RE, Stahl S. Last episode psychosis. Acta Psychiatr Scand. 2009 Jun; 119(6):417-8. PMID: 19469724.
      View in: PubMed
    112. Stahl S. Fibromyalgia--pathways and neurotransmitters. Hum Psychopharmacol. 2009 Jun; 24 Suppl 1:S11-7. PMID: 19479906.
      View in: PubMed
    113. Stahl S, Briley M. Why psychiatrists should not ignore pain in their patients--focus on fibromyalgia? Hum Psychopharmacol. 2009 Jun; 24 Suppl 1:S1-2. PMID: 19479908.
      View in: PubMed
    114. Stahl S. Norepinephrine and dopamine regulate signals and noise in the prefrontal cortex. J Clin Psychiatry. 2009 May; 70(5):617-8. PMID: 19552863.
      View in: PubMed
    115. Stahl S, Davis RL. Applying the principles of adult learning to the teaching of psychopharmacology: overview and finding the focus. CNS Spectr. 2009 Apr; 14(4):179-82. PMID: 19407729.
      View in: PubMed
    116. Stahl S. Vasomotor symptoms and depression in women, part 2. Treatments that cause remission and prevent relapses of major depressive episodes overlap with treatments for vasomotor symptoms. J Clin Psychiatry. 2009 Mar; 70(3):310-1. PMID: 19317957.
      View in: PubMed
    117. Stahl S. Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectr. 2009 Feb; 14(2):71-3. PMID: 19238121.
      View in: PubMed
    118. Stahl S. Vasomotor symptoms and depression in women, part I. Role of vasomotor symptoms in signaling the onset or relapse of a major depressive episode. J Clin Psychiatry. 2009 Jan; 70(1):11-2. PMID: 19222980.
      View in: PubMed
    119. Kim DH, Maneen MJ, Stahl S. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics. 2009 Jan; 6(1):78-85. PMID: 19110200.
      View in: PubMed
    120. Stahl S. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec; 13(12):1027-38. PMID: 19179941.
      View in: PubMed
    121. Stahl S. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry. 2008 Nov; 69(11):1673-4. PMID: 19200426.
      View in: PubMed
    122. Stahl S, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008 Oct; 13(10):855-70. PMID: 18955941.
      View in: PubMed
    123. Stahl S. L-methylfolate: a vitamin for your monoamines. J Clin Psychiatry. 2008 Sep; 69(9):1352-3. PMID: 19193337.
      View in: PubMed
    124. Wise DD, Felker A, Stahl S. Tailoring treatment of depression for women across the reproductive lifecycle: the importance of pregnancy, vasomotor symptoms, and other estrogen-related events in psychopharmacology. CNS Spectr. 2008 Aug; 13(8):647-62. PMID: 18704021.
      View in: PubMed
    125. Papakostas GI, Stahl S, Krishen A, Seifert CA, Tucker VL, Goodale EP, Fava M. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry. 2008 Aug; 69(8):1287-92. PMID: 18605812.
      View in: PubMed
    126. Stahl S, Wise DD. The potential role of a corticotropin-releasing factor receptor-1 antagonist in psychiatric disorders. CNS Spectr. 2008 Jun; 13(6):467-83. PMID: 18567971.
      View in: PubMed
    127. Cutler A, Ball S, Stahl S. Dosing atypical antipsychotics. CNS Spectr. 2008 May; 13(5 Suppl 9):1-16. PMID: 18496483.
      View in: PubMed
    128. Stahl S. Do dopamine partial agonists have partial efficacy as antipsychotics? CNS Spectr. 2008 Apr; 13(4):279-82. PMID: 18408646.
      View in: PubMed
    129. Stahl S. Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology? CNS Spectr. 2008 Feb; 13(2):115-8. PMID: 18227742.
      View in: PubMed
    130. Zisook S, Glick ID, Jefferson JW, Wagner KD, Salzman C, Peselow ED, Stahl S. Teaching psychopharmacology: what works and what doesn't. J Clin Psychopharmacol. 2008 Feb; 28(1):96-100. PMID: 18204350.
      View in: PubMed
    131. Rupnow MF, Greenspan A, Gharabawi GM, Kosik-Gonzalez C, Zhu Y, Stahl S. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr Med Res Opin. 2007 Nov; 23(11):2815-22. PMID: 17910802.
      View in: PubMed
    132. Stahl S. Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. CNS Spectr. 2007 Oct; 12(10):739-44. PMID: 17934378.
      View in: PubMed
    133. Stahl S, Ahmed S, Haudiquet V. Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. CNS Spectr. 2007 Sep; 12(9):703-11. PMID: 17805217.
      View in: PubMed
    134. Stahl S. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol. 2007 Oct; 10(5):575-8. PMID: 17681087.
      View in: PubMed
    135. Stahl S. The genetics of schizophrenia converge upon the NMDA glutamate receptor. CNS Spectr. 2007 Aug; 12(8):583-8. PMID: 17667886.
      View in: PubMed
    136. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl S, Williams KE. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci. 2007 Jul; 28(7):316-25. PMID: 17573127.
      View in: PubMed
    137. Stahl S. Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors. CNS Spectr. 2007 Jun; 12(6):423-7. PMID: 17545952.
      View in: PubMed
    138. Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl S, Keane P, Avenet P, Scatton B, le Fur G, Griebel G. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology. 2008 Feb; 33(3):574-87. PMID: 17460614.
      View in: PubMed
    139. Stahl S. Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectr. 2007 Apr; 12(4):265-8. PMID: 17426663.
      View in: PubMed
    140. Stahl S. Overview of trends in modern psychopharmacology. CNS Spectr. 2007 Feb; 12(2):103-5. PMID: 17277709.
      View in: PubMed
    141. Stahl S. Positive findings for negative symptoms of schizophrenia: no longer untreatable? Acta Psychiatr Scand. 2006 Nov; 114(5):301-2. PMID: 17022789.
      View in: PubMed
    142. Rausch JL, Johnson ME, Kasik KE, Stahl S. Temperature regulation in depression: functional 5HT1A receptor adaptation differentiates antidepressant response. Neuropsychopharmacology. 2006 Oct; 31(10):2274-80. PMID: 16641936.
      View in: PubMed
    143. Stahl S, Grady MM. High-cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv. 2006 Jan; 57(1):127-9. PMID: 16399974.
      View in: PubMed
    144. Stahl S. Finding what you are not looking for: strategies for developing novel treatments in psychiatry. NeuroRx. 2006 Jan; 3(1):3-9. PMID: 16490409; PMCID: PMC3593354.
    145. Stahl S, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005 Sep; 10(9):732-47. PMID: 16142213.
      View in: PubMed
    146. Shayegan DK, Stahl S. Emotion processing, the amygdala, and outcome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun; 29(5):840-5. PMID: 15925435.
      View in: PubMed
    147. Stahl S. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr. 2005 Apr; 10(4):319-23. PMID: 15788959.
      View in: PubMed
    148. Citrome L, Goldberg JF, Stahl S. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry. 2005 Jan-Feb; 13(1):28-42. PMID: 15804932.
      View in: PubMed
    149. Stahl S. Is psychopharmacologic "inoculation" effective in preventing posttraumatic stress disorder? J Clin Psychiatry. 2005 Jan; 66(1):5-6. PMID: 15669882.
      View in: PubMed
    150. Fava M, Rush AJ, Thase ME, Clayton A, Stahl S, Pradko JF, Johnston JA. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005; 7(3):106-13. PMID: 16027765; PMCID: PMC1163271.
    151. Stahl S. Preemptive analgesia: is pain less costly when you pre-pay for it? J Clin Psychiatry. 2004 Dec; 65(12):1591-2. PMID: 15641861.
      View in: PubMed
    152. Shelton RC, Stahl S. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004 Dec; 65(12):1715-9. PMID: 15641878.
      View in: PubMed
    153. Stahl S. Prophylactic antipsychotics: do they keep you from catching schizophrenia? J Clin Psychiatry. 2004 Nov; 65(11):1445-6. PMID: 15554754.
      View in: PubMed
    154. Demyttenaere K, De Fruyt J, Stahl S. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol. 2005 Mar; 8(1):93-105. PMID: 15482632.
      View in: PubMed
    155. Shayegan DK, Stahl S. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr. 2004 Oct; 9(10 Suppl 11):6-14. PMID: 15475871.
      View in: PubMed
    156. Stahl S. Drug combinations for bipolar spectrum disorders: evidence-based prescribing or prescribing-based evidence? J Clin Psychiatry. 2004 Oct; 65(10):1298-9. PMID: 15491230.
      View in: PubMed
    157. Stahl S, Freudenreich O, Goff D. A successful antipsychotic combination trial. Quo Vadis? Acta Psychiatr Scand. 2004 Oct; 110(4):241-2. PMID: 15352924.
      View in: PubMed
    158. Stahl S, Briley M. Understanding pain in depression. Hum Psychopharmacol. 2004 Oct; 19 Suppl 1:S9-S13. PMID: 15378669.
      View in: PubMed
    159. Stahl S. Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. J Clin Psychiatry. 2004 Sep; 65(9):1162-3. PMID: 15367040.
      View in: PubMed
    160. Gelenberg AJ, Shelton RC, Crits-Christoph P, Keller MB, Dunner DL, Hirschfeld RM, Thase ME, Russell JM, Lydiard RB, Gallop RJ, Todd L, Hellerstein DJ, Goodnick PJ, Keitner GI, Stahl S, Halbreich U, Hopkins HS. The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. J Clin Psychiatry. 2004 Aug; 65(8):1114-9. PMID: 15323598.
      View in: PubMed
    161. Stahl S. Mechanism of action of alpha2delta ligands: voltage sensitive calcium channel (VSCC) modulators. J Clin Psychiatry. 2004 Aug; 65(8):1033-4. PMID: 15323585.
      View in: PubMed
    162. Stahl S. Mechanism of action of voltage sensitive sodium channel modulators. J Clin Psychiatry. 2004 Jul; 65(7):894-5. PMID: 15291674.
      View in: PubMed
    163. Stahl S. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. J Clin Psychiatry. 2004 Jun; 65(6):738-9. PMID: 15291647.
      View in: PubMed
    164. Stahl S. Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J Clin Psychiatry. 2004 May; 65(5):596-7. PMID: 15163243.
      View in: PubMed
    165. Stahl S, Markowitz JS, Papadopoulos G, Sadik K. Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Curr Med Res Opin. 2004 Apr; 20(4):517-24. PMID: 15119989.
      View in: PubMed
    166. Stahl S. Anticonvulsants as anxiolytics, part 2: Pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J Clin Psychiatry. 2004 Apr; 65(4):460-1. PMID: 15119905.
      View in: PubMed
    167. Stahl S. Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA. J Clin Psychiatry. 2004 Mar; 65(3):291-2. PMID: 15096065.
      View in: PubMed
    168. Stahl S. Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence? Int J Neuropsychopharmacol. 2004 Jun; 7(2):113-6. PMID: 14984629.
      View in: PubMed
    169. Stahl S. Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action? J Clin Psychiatry. 2004 Feb; 65(2):149-50. PMID: 15003065.
      View in: PubMed
    170. Stahl S, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry. 2004; 6(4):159-166. PMID: 15361919.
      View in: PubMed
    171. Stahl S. Selectivity of SSRIs: individualising patient care through rational treatment choices. Int J Psychiatry Clin Pract. 2004; 8 Suppl 1:3-10. PMID: 24930682.
      View in: PubMed
    172. Stahl S. Symptoms and circuits, part 3: schizophrenia. J Clin Psychiatry. 2004 Jan; 65(1):8-9. PMID: 14744162.
      View in: PubMed
    173. Stahl S. Brainstorms: symptoms and circuits, part 2: anxiety disorders. J Clin Psychiatry. 2003 Dec; 64(12):1408-9. PMID: 14728099.
      View in: PubMed
    174. Stahl S. Symptoms and circuits, part 1: major depressive disorder. J Clin Psychiatry. 2003 Nov; 64(11):1282-3. PMID: 14658940.
      View in: PubMed
    175. Stahl S, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2003 Nov; 64(11):1322-7. PMID: 14658946.
      View in: PubMed
    176. Stahl S. Deconstructing psychiatric disorders, part 2: An emerging, neurobiologically based therapeutic strategy for the modern psychopharmacologist. J Clin Psychiatry. 2003 Oct; 64(10):1145-6. PMID: 14658960.
      View in: PubMed
    177. Stahl S. Deconstructing psychiatric disorders, Part 1. Genotypes, symptom phenotypes, and endophenotypes. J Clin Psychiatry. 2003 Sep; 64(9):982-3. PMID: 14628971.
      View in: PubMed
    178. Stahl S. Here today and not gone tomorrow: the curse of chronic pain and other central sensitization syndromes. J Clin Psychiatry. 2003 Aug; 64(8):863-4. PMID: 12926998.
      View in: PubMed
    179. Stahl S. Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes. J Clin Psychiatry. 2003 Jul; 64(7):745-6. PMID: 12934972.
      View in: PubMed
    180. Stahl S. The ups and downs of novel antiemetic drugs, part 2: an illustration. J Clin Psychiatry. 2003 Jun; 64(6):626-7. PMID: 12823074.
      View in: PubMed
    181. Stahl S. The ups and downs of novel antiemetic drugs, part 1: substance P, 5-HT, and the neuropharmacology of vomiting. J Clin Psychiatry. 2003 May; 64(5):498-9. PMID: 12755650.
      View in: PubMed
    182. Stahl S. At long last, long-lasting psychiatric medications: an overview of controlled-release technologies. J Clin Psychiatry. 2003 Apr; 64(4):355-6. PMID: 12716234.
      View in: PubMed
    183. Stahl S, Markowitz JS, Gutterman EM, Papadopoulos G. Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. J Clin Psychiatry. 2003 Apr; 64(4):466-72. PMID: 12716251.
      View in: PubMed
    184. Stahl S. Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex. J Clin Psychiatry. 2003 Mar; 64(3):230-1. PMID: 12716261.
      View in: PubMed
    185. Stahl S. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry. 2003 Feb; 64(2):110-1. PMID: 12633117.
      View in: PubMed
    186. Stahl S, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003; 64 Suppl 19:6-12. PMID: 14728084.
      View in: PubMed
    187. Stahl S. Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. J Clin Psychiatry. 2003 Jan; 64(1):4-5. PMID: 12590617.
      View in: PubMed
    188. Hollander E, Kaplan A, Stahl S. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry. 2003 Jan; 4(1):30-4. PMID: 12582975.
      View in: PubMed
    189. Stahl S, Grady MM. Differences in mechanism of action between current and future antidepressants. J Clin Psychiatry. 2003; 64 Suppl 13:13-7. PMID: 14552651.
      View in: PubMed
    190. Stahl S. Introduction: optimizing wakefulness in patients with fatigue and executive dysfunction. J Clin Psychiatry. 2003; 64 Suppl 14:3-4. PMID: 14658928.
      View in: PubMed
    191. Stahl S, Zhang L, Damatarca C, Grady M. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry. 2003; 64 Suppl 14:6-17. PMID: 14658930.
      View in: PubMed
    192. Stahl S, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry. 2002 Dec 15; 52(12):1166-74. PMID: 12488062.
      View in: PubMed
    193. Stahl S. The metabolic syndrome: psychopharmacologists should weigh the evidence for weighing the patient. J Clin Psychiatry. 2002 Dec; 63(12):1094-5. PMID: 12523866.
      View in: PubMed
    194. Lutz W, Stahl S, Howard KI, Grissom GR, Joske R. Some relationships among assessments of depression. J Clin Psychol. 2002 Dec; 58(12):1545-53. PMID: 12455021.
      View in: PubMed
    195. Stahl S. Can psychopharmacologic treatments that relieve symptoms also prevent disease progression? J Clin Psychiatry. 2002 Nov; 63(11):961-2. PMID: 12444807.
      View in: PubMed
    196. Stahl S. Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents. J Clin Psychiatry. 2002 Oct; 63(10):854-5. PMID: 12416593.
      View in: PubMed
    197. Stahl S. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry. 2002 Sep; 63(9):756-7. PMID: 12363113.
      View in: PubMed
    198. Stahl S, Mendels J, Schwartz GE. Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials. J Clin Psychopharmacol. 2002 Aug; 22(4):388-92. PMID: 12172338.
      View in: PubMed
    199. Stahl S. Mirror, mirror on the wall, which enantiomer is fairest of them all? J Clin Psychiatry. 2002 Aug; 63(8):656-7. PMID: 12197444.
      View in: PubMed
    200. Stahl S. Psychopharmacology of wakefulness: pathways and neurotransmitters. J Clin Psychiatry. 2002 Jul; 63(7):551-2. PMID: 12143908.
      View in: PubMed
    201. Stahl S. Awakening to the psychopharmacology of sleep and arousal: novel neurotransmitters and wake-promoting drugs. J Clin Psychiatry. 2002 Jun; 63(6):467-8. PMID: 12088156.
      View in: PubMed
    202. Stahl S. The psychopharmacology of painful physical symptoms in depression. J Clin Psychiatry. 2002 May; 63(5):382-3. PMID: 12019660.
      View in: PubMed
    203. Stahl S. Does depression hurt? J Clin Psychiatry. 2002 Apr; 63(4):273-4. PMID: 12000200.
      View in: PubMed
    204. Stahl S. Selective actions on sleep or anxiety by exploiting GABA-A/benzodiazepine receptor subtypes. J Clin Psychiatry. 2002 Mar; 63(3):179-80. PMID: 11926714.
      View in: PubMed
    205. Stahl S. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry. 2002 Feb; 63(2):93-4. PMID: 11874226.
      View in: PubMed
    206. Stahl S. The psychopharmacology of energy and fatigue. J Clin Psychiatry. 2002 Jan; 63(1):7-8. PMID: 11838630.
      View in: PubMed
    207. Stahl S, Kaiser L, Roeschen J, Keppel Hesselink JM, Orazem J. Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. Int J Neuropsychopharmacol. 1998 Jul; 1(1):11-18. PMID: 11281940.
      View in: PubMed
    208. Lerer B, Frazer A, Stahl S, Farde L, Lesch P. The International Journal of Neuropsychopharmacology. Int J Neuropsychopharmacol. 1998 Jul; 1(1):1-2. PMID: 11343572.
      View in: PubMed
    Stephen's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _